Phase 3 Results of Inhaled Treprostinil in Patients With Idiopathic Pulmonary Fibrosis by Madaline Spencer| Published on: Sep 25, 2026

Phase 3 Results of Inhaled Treprostinil in Patients With Idiopathic Pulmonary Fibrosis by Madaline Spencer| Published on: Sep 25, 2026 A study published in The New England Journal of Medicine examined results from the phase 3 TETON-1 clinical trial of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF). IPF is a rare, progressive disorder characterized by the progressive scarring of tissues in the lungs. Common symptoms include shortness of breath and a dry, hacking cough. In some cases fibrosis happens quickly, while in others, the process is slower. The cause of IPF is unknown. It is most often diagnosed in patients aged 60 to 70 years. https://checkrare.com/phase-3-results-of-inhaled-treprostinil-in-patients-with-idiopathic-pulmonary-fibrosis/